Nyenhuis David L, Gorelick Philip B
Department of Neurology and Rehabilitation Medicine, University of Illinois at Chicago, Center for Stroke Research, 1645 West Jackson Boulevard, Suite #400, Chicago, IL 60612, USA.
Curr Atheroscler Rep. 2007 Oct;9(4):326-32. doi: 10.1007/s11883-007-0040-5.
Accurate diagnosis of vascular cognitive impairment (VCI) is important but may be difficult. VCI diagnoses depend on determinations of the presence of both cognitive impairment and cerebrovascular disease (CVD), temporal causal links between cognitive impairment and CVD, and the presence or absence of other potential contributors to cognitive impairment, such as Alzheimer's disease (AD). Diagnostic criteria differ across currently utilized systems, resulting in widely differing VCI prevalence rates. Also, current systems may not be able to differentiate "pure" VCI from "mixed" AD and CVD. National Institute of Neurological Disorders and Stroke harmonization criteria for VCI have been developed for study and validation to help bridge gaps in our understanding of VCI diagnosis. VCI management begins with atherogenic risk factor control. Current VCI treatment options demonstrate statistical improvement but not consistent global clinical efficacy. Future clinical trials should concentrate on both primary risk factor control and development of new therapeutic agents to treat patients already diagnosed with VCI.
准确诊断血管性认知障碍(VCI)很重要,但可能具有挑战性。VCI的诊断取决于对认知障碍和脑血管疾病(CVD)的存在、认知障碍与CVD之间的时间因果关系,以及是否存在其他导致认知障碍的潜在因素,如阿尔茨海默病(AD)。目前使用的诊断系统标准各异,导致VCI患病率差异很大。此外,当前系统可能无法区分“单纯”VCI与“混合性”AD和CVD。美国国立神经疾病和中风研究所已经制定了VCI的协调标准用于研究和验证,以帮助弥合我们对VCI诊断理解上的差距。VCI的管理始于控制动脉粥样硬化风险因素。目前的VCI治疗方案显示出统计学上的改善,但全球临床疗效并不一致。未来的临床试验应专注于主要风险因素的控制以及开发新的治疗药物,以治疗已确诊VCI的患者。